Glenmark Pharma's subsidiaries receive approval of ‘Ryaltris' in Canada

23 Sep 2022 , 09:47 AM

Bausch Health Companies Inc. (Bausch Health) and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), announced that Health Canada has approved RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray).

Ryaltris is used for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6.

Ryaltris is a fixed-dose combination medication that relieves both nasal and ocular SAR symptoms in a single, easy-to-use nasal spray. The impact of RYALTRIS for nasal symptom alleviation begins within 15 minutes after dosing, stated the company in its media release.

“With this Health Canada clearance, Bausch Health will be able to make RYALTRIS available to Canadians very soon, giving a novel therapeutic option for seasonal allergic rhinitis,” stated Cees Heiman, Senior Vice-President, Europe and Canada at Bausch Health.

At around 9.51 AM, Glenmark Pharmaceuticals was trading at Rs386.45 down by 0.41% from its previous closing of Rs388.05 on the BSE. The scrip opened at Rs385.90 and touched intraday high and low of Rs389.15 and Rs384 respectively.

For feedback and suggestions, write to us at [e-mail]